
MHC class II, Mouse, mAb ER-TR3
The monoclonal antibody ER-TR3 reacts with mouse major histocompatibitity complex class II (MHC class II), also known as I-A or I-E. MHC class II molecules are heterodimers of non-covalently associated alpha (31-34 kDa) and beta (26-29 kDa) chains. Major histocompatibility complex class II antigen presentation requires the participation of lysosomal proteases in two convergent processes. First, the antigens endocytosed by the antigen-presenting cells must be broken down into antigenic peptides. Second, class II molecules are synthesized with their peptide-binding site blocked by invariant chain (Ii), and they acquire the capacity to bind antigens only after Ii has been degraded in the compartments where peptides reside. MHC class II molecules present exogenously derived antigen to CD4+ T lymphocytes, which are usually T helper cells. CD4 interacts with non-polymorphic residues of MHC Class II. The monoclonal antibody ER-TR3 is a valuable tool for studying T helper cell interaction with class II positive antigen presenting cells (dendritic cells, B cells and macrophages) and for studying the development of T helper cells since they stain stromal cells in thymus. The level of antigen detected by ER-TR3 differs from strain to strain. The monoclonal antibody ER-TR3 cross reacts with human MHC class II on tonsil. Distribution of ER-TR3 among mouse strains with independent and recombinant haplotypes.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- Discover Cross-Reactive Complement ELISA for NHP ResearchBridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following initiative: Testing our existing complement ELISA assays for NHP research. Why Non Human Primate Samples… Read more: Discover Cross-Reactive Complement ELISA for NHP Research
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis